Top 5 Health Care Stocks That May Explode In Q3
Portfolio Pulse from Lisa Levin
The article lists the top 5 oversold health care stocks that may explode in Q3. These include BioVie Inc. (BIVI), 23andMe Holding Co. (ME), Singular Genomics Systems, Inc. (OMIC), Galera Therapeutics, Inc. (GRTX), and iSpecimen Inc. (ISPC). All these stocks have an RSI value below 30, indicating they are oversold and may rebound.
September 06, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioVie Inc. presented data for NE3107 at the 2023 International Congress of Parkinson's Disease and Movement Disorders. Its stock has a 52-week low of $1.96 and an RSI value of 26.01.
BioVie's recent presentation of data for NE3107 could potentially boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Galera Therapeutics, Inc. posted a wider-than-expected quarterly loss. Its stock has a 52-week low of $0.1960 and an RSI value of 16.72.
Despite the wider-than-expected quarterly loss, Galera Therapeutics' oversold status could potentially attract bargain hunters and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 65
RELEVANCE 100
POSITIVE IMPACT
iSpecimen Inc. launched a new virtual cancer sequencing procurement program. Its stock has a 52-week low of $0.6818 and an RSI value of 21.05.
iSpecimen's launch of a new virtual cancer sequencing procurement program could potentially boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
23andMe Holding Co. received FDA 510(k) clearance to expand its existing BRCA1/BRCA2 Genetic Health Risk Report. Its stock has a 52-week low of $0.9870 and an RSI value of 29.59.
The FDA clearance for 23andMe's health risk report could potentially increase investor interest and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Singular Genomics Systems, Inc. posted a narrower-than-expected quarterly loss. Its stock has a 52-week low of $0.4560 and an RSI value of 14.80.
Singular Genomics' better-than-expected quarterly results could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100